Skip to content
Research Article Open access CC BY 4.0

Impact of Comorbid Conditions in COVID-19 Treatment

Touseef Ahmed, Toqeer Hussain, Maryem Arif, Nadeem Iqbal, Zubair Ahmed Khoso

Journal of Pharmaceutical Research International · pp. 30–37 · Published 9 Jun 2022

10.9734/jpri/2022/v34i41A36272

Abstract

In 2019, an outbreak known as SARS-CoV-2 spread all over the World from China city Wuhan. This epidemic rapidly spread throughout the world from that day, affecting 180 nations. Individuals of all ages were involved in this outbreak, and this spread at a high rate. COVID-19 is thought to lead to death due to its increasingly fast and severe course in people with serious health issues and complications. In this paper the impact of comorbid condition in COVID-19 treatment was investigated. To conduct an automated literature review, statistical information from published articles was gathered between January 20 and April 20, 2020. Immunocompromised patients might be more prone to acquire COVID-19 compared to healthy individuals. Additionally, people with dementia, those 65 years and above, who had comorbidities and COVID-19 had more chance of getting admitted to ICU and dying. That is why immunocompromised patients need more care and attention so that they might not be affected by this outbreak, which may lead to their death.

Comorbid conditions COVID-19 treatment

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.